Search Results

Your search for Syed Ali Abutalib, MD, and Bruce L. Levine, PhD matches 2 pages

Showing 1 - 2

By Syed Ali Abutalib, MD, and Bruce L. Levine, PhD / February 25, 2019

Update on FDA-Approved CAR T-Cell Products

AXICABTAGENE CILOLEUCEL (also known as CAR19) is an anti-CD19 chimeric antigen receptor (CAR) T-cell product approved by U.S. Food and Drug Administration to treat selected hematologic malignancies.1 To appreciate the clinical trial findings summarized here, from selected abstracts presented at the ...

lymphoma

leukemia

immunotherapy

By Syed Ali Abutalib, MD, and Bruce L. Levine, PhD / February 25, 2019

Update on FDA-Approved CAR T-Cell Products

TISAGENLECLEUCEL IS an anti-CD19 chimeric antigen receptor (CAR) T-cell product approved by U.S. Food and Drug Administration to treat selected hematologic malignancies.1,2 To appreciate the clinical trial findings summarized here, from selected abstracts presented at the 2018 American Society of...

Apr

Today In Oncology

Search Results

Your search for Syed Ali Abutalib, MD, and Bruce L. Levine, PhD matches 2 pages

Update on FDA-Approved CAR T-Cell Products

Update on FDA-Approved CAR T-Cell Products

Alectinib Approved as Adjuvant Treatment for ALK-Positive Non–Small Cell Lung Cancer

Professional Societies Introduce New Evidence-Based Guidelines on Testing Immunotherapy Biomarkers in NSCLC

Accelerated Aging May Be a Risk Factor for Early-Onset Cancers in Younger Generations

Novel MDM2 Inhibitor Shows Activity in Salivary Gland Cancers

Novel SPECT/CT Imaging Technique Under Study in Prostate Cancer